Shionogi-ViiV Healthcare Starts Phase III Trial for “572-Trii” Fixed-Dose Combination HIV Therapy London, UK, 3 February 2011 – Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the c - Combination therapy - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-11-03 11:26:17 Organic chemistry Organofluorides Gilead Sciences Cyclopropanes Purines Abacavir/lamivudine Abacavir Lamivudine Fixed-dose combination Medicine Chemistry Fixed dose combination		Shionogi-ViiV Healthcare Starts Phase III Trial for “572-Trii” Fixed-Dose Combination HIV Therapy London, UK, 3 February 2011 – Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the c Add to Reading List Source URL: shionogi616.tew-staging.com Download Document from Source Website File Size: 28,99 KB Share Document on Facebook

	Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No DocID: 1rqYi - View Document
	GENERAL CONFORMITY CERTIFICATE This is an electronically controlled document. User is responsible for verifying and using the effective version. Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that bas DocID: 1pCJo - View Document
	Microsoft Word - GOCER-028.docx DocID: 1pkag - View Document
	GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a reasonable testing program, the product referenced in this certificate complies with applicable regulations DocID: 1oSag - View Document
	BMS_Gilead_Logo_FINAL.eps DocID: 1m38a - View Document